Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Abivax
Companies To Watch: Abivax With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection.  It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).  Continue Reading...
  • Industry Explorers Blaze On: Deborah Dunsire
    Industry Explorers Blaze On: Deborah Dunsire

    Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.

  • Companies To Watch: Madrigal Pharmaceuticals
    Companies To Watch: Madrigal Pharmaceuticals

    Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.

  • Prometic: New Tech Harvests Orphan Treatments
    Prometic: New Tech Harvests Orphan Treatments

    Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.

  • Cytokinetics: Keeping Its Sights On Independence
    Cytokinetics: Keeping Its Sights On Independence

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  • Companies To Watch: Arena Pharmaceuticals
    Companies To Watch: Arena Pharmaceuticals

    By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.

  • The Mechanics Of Hyperbole
    The Mechanics Of Hyperbole

    Oncology isn’t the only therapeutic area subject to the hyperbole of hope. It is just the most perfect example of hype, an all-too-common state of mind in the “cancer community.

  • Ipsen In The USA — Building & Leading The Subsidiary As Startup
    Ipsen In The USA — Building & Leading The Subsidiary As Startup

    Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.

  • Companies To Watch: ProMIS Neurosciences
    Companies To Watch: ProMIS Neurosciences

    ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.

  • Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion
    Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion

    As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.

  • The Solar Eclipse And Other Irrelevancies
    The Solar Eclipse And Other Irrelevancies

    As a trade journalist, I often face the challenge of relevancy. Is what I’m writing about really useful and germane to readers as members of a particular industry?

  • Companies To Watch: GeNeuro
    Companies To Watch: GeNeuro

    Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.

  • Astellas Puts Oncology Front & Center
    Astellas Puts Oncology Front & Center

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.

  • An Introvert’s View Of The Industry — Or Travels With Incredulity
    An Introvert’s View Of The Industry — Or Travels With Incredulity

    When I leave my writer’s lair and go out into the world, I feel like the tortoise in a race of hares. People move around me at the speed of light, most lost in their screens, smiling at machines.

  • Companies To Watch: Frequency Therapeutics
    Companies To Watch: Frequency Therapeutics

    Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.